Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our medical information is accurate, up to date, and scientifically balanced.

CYKLOKAPRON®(tranexamic acid)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our medical information is accurate, up to date, and scientifically balanced.

CYKLOKAPRON® Quick Finder

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the...
Did you find an answer to your question? Yes No

1 INDICATIONS AND USAGE

CYKLOKAPRON® is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and...

Did you find an answer to your question? Yes No

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

The recommended dose of CYKLOKAPRON is 10 mg/kg actual body weight intravenously administered as a single dose,...

Did you find an answer to your question? Yes No

3 DOSAGE FORMS AND STRENGTHS

Injection: 1,000 mg tranexamic acid (100 mg/mL) clear and colorless solution in 10 mL single-dose ampules

Injection: 1,000 mg tranexamic acid (100 mg/mL) clear and colorless solution in 10...

Did you find an answer to your question? Yes No

4 CONTRAINDICATIONS

CYKLOKAPRON Injection is contraindicated:

  • In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by CYKLOKAPRON in...
Did you find an answer to your question? Yes No

5 WARNINGS AND PRECAUTIONS

5.1 Thromboembolic Risk

CYKLOKAPRON is contraindicated in patients with active intravascular clotting.

Tranexamic acid is an...

Did you find an answer to your question? Yes No

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Thromboembolic Risk [see

    6.2 Postmarketing Experience...

Did you find an answer to your question? Yes No

7 DRUG INTERACTIONS

7.1 Prothrombotic Medical Products

Avoid concomitant use of CYKLOKAPRON with medical products that are prothrombotic because concomitant use...

Did you find an answer to your question? Yes No

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available data from...

Did you find an answer to your question? Yes No

10 OVERDOSAGE

Cases of overdosage of CYKLOKAPRON have been reported. Based on these reports, symptoms of overdosage may be gastrointestinal, e.g., nausea, vomiting, diarrhea; hypotensive, e.g., orthostatic symptoms;...

Did you find an answer to your question? Yes No

11 DESCRIPTION

Tranexamic acid is trans-4-(aminomethyl)cyclohexanecarboxylic acid, an antifibrinolytic agent. Tranexamic acid is a white crystalline powder. The structural formula is

...

Did you find an answer to your question? Yes No

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin...

Did you find an answer to your question? Yes No

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Tranexamic acid was not carcinogenic in a 2-year study in rats and mice at oral...

Did you find an answer to your question? Yes No

16 HOW SUPPLIED/STORAGE AND HANDLING

...
Did you find an answer to your question? Yes No

17 PATIENT COUNSELING INFORMATION

Thromboembolic Risk

Inform patients that CYKLOKAPRON may increase the risk of venous and arterial...

Did you find an answer to your question? Yes No

This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

...

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event